Department of Clinical Pharmacy and Toxicology, Martini Hospital, Van Swietenplein 1, 9728 NT Groningen, The Netherlands.
Department of PharmacoTherapy, -Epidemiology & -Economics (PTEE), Department of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
Europace. 2018 Jan 1;20(1):12-18. doi: 10.1093/europace/euw285.
Atrial fibrillation (AF) is the most common arrhythmia and prevalence increases with age. Patients with AF have a high risk of stroke, and screening for AF is recommended in all people aged 65 years or older to identify patients eligible for stroke prevention. A handheld, single-lead electrocardiogram (ECG) device can be used for systematic screening in the population at risk. The objective of this study is to estimate the cost-effectiveness of screening for AF in primary care with the MyDiagnostick® during seasonal influenza vaccination in the Netherlands.
Lifetime costs and effects of a single screening session for AF detection were assessed from a societal perspective with a decision analytic model consisting of a straightforward decision tree and a joining Markov model. The decision model simulated all patients aged 65 years and over attending the seasonal influenza vaccination in the Netherlands. Event probabilities were derived from clinical trials. Sensitivity analyses were performed to assess the impact of important model assumptions as well as determining the relative effect of individual parameters. Screening for AF with the MyDiagnostick® in all patients older than 65 years that attend seasonal influenza vaccination in the Netherlands would decrease the overall costs by €764 and increase the quality-adjusted life-years (QALYs) by 0.27 years per patient. Early detection of AF would prevent strokes and leads to beneficial health effects with subsequent cost savings. This screening method would have an estimated probability of 99.8% for being cost-effective at a conservative willingness-to-pay of €20 000/QALY.
Screening for AF in primary care with a handheld, single-lead ECG during seasonal influenza vaccination is very likely to be cost saving for identifying new cases of AF in the Dutch population aged 65 years and over. Active screening for AF with a single-lead, handheld ECG device during seasonal influenza vaccination could be implemented in primary care.
心房颤动(AF)是最常见的心律失常,其患病率随着年龄的增长而增加。AF 患者中风风险较高,建议对所有 65 岁及以上的人进行 AF 筛查,以确定有资格进行中风预防的患者。手持式单导联心电图(ECG)设备可用于对高危人群进行系统筛查。本研究旨在评估在荷兰季节性流感疫苗接种期间使用 MyDiagnostick®对初级保健中的 AF 进行筛查的成本效益。
从社会角度评估了单次 AF 检测筛查的终生成本和效果,该模型采用由直接决策树和联合马尔可夫模型组成的决策分析模型。决策模型模拟了所有在荷兰接受季节性流感疫苗接种的 65 岁及以上患者。事件概率源自临床试验。进行了敏感性分析,以评估重要模型假设的影响,以及确定单个参数的相对影响。在荷兰,对所有年龄大于 65 岁且参加季节性流感疫苗接种的患者进行 AF 筛查,将降低总体成本 764 欧元,并使每位患者的质量调整生命年(QALY)增加 0.27 年。早期发现 AF 可预防中风,并带来有益的健康效果,从而节省后续成本。这种筛查方法在保守的每 QALY 20000 欧元的支付意愿下,具有 99.8%的成本效益估计概率。
在初级保健中使用手持式单导联 ECG 对季节性流感疫苗接种进行 AF 筛查,非常有可能为识别荷兰 65 岁及以上人群中的新 AF 病例节省成本。在季节性流感疫苗接种期间,使用单导联、手持式 ECG 设备主动筛查 AF,可以在初级保健中实施。